Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
A monoclonal natural human IgM protects axons in the absence of remyelination.
Biomarkers of disease activity in multiple sclerosis.
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Clinically isolated syndromes.
FDA product review for daclizumab
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Sex hormones and multiple sclerosis: another informative failure.
You-Gui pills promote nerve regeneration by regulating netrin1, DCC and Rho family GTPases RhoA, Racl, Cdc42 in C57BL/6 mice with experimental autoimmune encephalomyelitis.
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
Daytime sleepiness versus fatigue in patients with multiple sclerosis: A systematic review on the Epworth sleepiness scale as an assessment tool.
Dimethylfumarate induces apoptosis in human mast cells.
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus.
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis.
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Multiple sclerosis: association with HL-A3.
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
CHMP issues positive opinion for TECFIDERA™ (dimethyl fumarate) as a first-line treatment for multiple sclerosis in the European Union
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients.
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Policy: NIH to balance sex in cell and animal studies.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis.

Pages